FDA approves Zepbound (tirzepatide) for chronic weight management
Today, the FDA approved Zepbound (tirzepatide) for chronic weight management in people with a BMI of 30 or greater or a BMI of 27 or greater with at least one related medical condition such as high blood pressure, diabetes, high cholesterol, fatty liver or sleep apnea.
Tirzepatide had already been approved as Mounjaro for diabetes type 2 management in both the US and Canada. Now we await Health Canada's decision regarding Zepbound for chronic weight management.
By the way, who comes up with names like Zepbound?!?
Read the full FDA release here:
https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
#tirzepatide #Zepbound
